MDxHealth SA
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MDXH in the last 30 days.
See all $MDXH insider activity →BTIG downgraded MDxHealth (MDXH) to Neutral from Buy after Q3 revenue miss and suspended guidance. Stock fell 66% to $0.21. BTIG cited sales rep turnover and balance sheet concerns. MDxHealth has $105.85M debt, $19.71M market cap, and burning cash. Q2 revenue was $27.2M, beating estimates, but EPS missed. Full-year 2026 revenue guidance is $110M-$115M. BTIG previously cut price target to $2.00 from $4.00.
MDxHealth SA (MDXH) reported preliminary Q3 2026 revenue of $22.7 million, matching the prior year, but below expectations. The company cited sales force turnover and discontinued product as reasons. CEO Michael K. McGarrity expects a return to growth and will provide more details on November 12.
MDxHealth (MDXH) reported a 14% revenue increase to $51.1M for H1 2026, but net loss rose 18% to $19.2M due to higher operating expenses. Gross margin fell 4.2 points to 63.7%. The company faces going-concern doubts amid an accumulated deficit of $423.4M and expects continued losses.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning MDXH (MDxHealth SA). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent MDXH coverage spans financial news, earnings and insider activity.
The downgrade removes a bullish price target and highlights balance‑sheet concerns, likely prompting sellers.
Guidance suspension and sales-force disruption raise downside risk to 2026 revenue trajectory until the Nov. 12 results clarify stabilization and demand.
The interim loss and cash burn raise short‑term risk, likely pressuring the stock lower.
Target reduction suggests bearish outlook.
Earnings beat revenue growth but widened losses; guidance suggests return to adjusted EBITDA profitability later this year.
AlphAI scores every news story that mentions MDXH with an AI model for sentiment and relevance, and aggregates insider trades from MDxHealth SA's SEC EDGAR Form 4 filings. Figures refresh continuously.
BTIG downgraded MDxHealth (MDXH) to Neutral from Buy after Q3 revenue miss and suspended guidance. Stock fell 66% to $0.21. BTIG cited sales rep turnover and balance sheet concerns. MDxHealth has $105.85M debt, $19.71M market cap, and burning cash. Q2 revenue was $27.2M, beating estimates, but EPS missed. Full-year 2026 revenue guidance is $110M-$115M. BTIG previously cut price target to $2.00 from $4.00.
2 min readMDxHealth SA (MDXH) reported preliminary Q3 2026 revenue of $22.7 million, matching the prior year, but below expectations. The company cited sales force turnover and discontinued product as reasons. CEO Michael K. McGarrity expects a return to growth and will provide more details on November 12.
4 min readMDxHealth (MDXH) reported a 14% revenue increase to $51.1M for H1 2026, but net loss rose 18% to $19.2M due to higher operating expenses. Gross margin fell 4.2 points to 63.7%. The company faces going-concern doubts amid an accumulated deficit of $423.4M and expects continued losses.
2 min readAnalysts updated price targets for several companies. Baird raised Ross Stores (ROST) target to $270, Parsons (PSN) to $57, and Deere (DE) to $640. BTIG cut Walmart (WMT) target to $140. HSBC raised Ternium (TX) target to $55. Rothschild & Co increased Equifax (EFX) target to $235. Other changes include Envoy Medical (COCH), MDxHealth (MDXH), Hometrust Bancshares (HTB), and Haemonetics (HAE).
2 min readMDxHealth reported Q2 2026 revenue of $27.2M, up 16% YoY, with gross profit at $17.9M. Operating loss increased to $5.1M, and net loss rose 36% to $9.5M. The company completed the wind-down of its Resolve UTI business. Management expressed confidence in meeting full-year revenue guidance of $110M-$115M and returning to adjusted EBITDA profitability by year-end, citing growth in its urology and prostate cancer diagnostics.
2 min readMDxHealth SA (MDXH) shareholders Laurence W. Lytton and the Lytton-Kambara Foundation filed a Schedule 13G/A reporting beneficial ownership of 18,558,988 and 11,583,098 Ordinary Shares, or 19.5% and 12.1%, respectively, based on 95,417,382 shares outstanding as of Aug. 13, 2026.
2 min readMVM Partners, LLC purchased 2,202,643 indirectly-held shares of MDxHealth SA (MDXH) at $0.45 ($1.00M total) on 2026-08-13. Filed jointly with Bednarski Eric (Director).
1 min readUS markets closed lower on Friday, with the Dow, NASDAQ, and S&P 500 falling 0.26%, 0.51%, and 0.24% respectively. Retail sales declined 0.6% in July, missing estimates, and consumer sentiment dropped to 51 in August. Energy stocks rose 1.3%, while tech fell 0.6%. Eton Pharmaceuticals (ETON) surged 39% on strong earnings, while KinderCare (KLC) fell 31% after missing expectations.
2 min readmdxhealth reported Q2 tissue-based test volume rose 13% sequentially to 12,525 tests, aiding Q2 revenue of $27.2 million, up 16% year over year. Revenue for the first half of 2026 rose 14% to $51.1 million. Liquid Exo mdx volume was 13,578 tests, shifting mix and lowering gross margin to 65.7%. Operating loss widened to $5.1 million. On Aug. 11 it raised $20 million via share placement.
4 min readThe article highlights microcaps with near-term catalysts. Kartoon Studios (TOON) reported Q2 2026 revenue of about $5.8M and EPS about $0.38, including a $39.2M litigation settlement gain, and said an Amazon Prime Video deal will launch in Feb 2027. SurgePays (SURG) posted Q2 revenue up 40.7% to $16.2M and GAAP net income $1.29M. MDxHealth (MDXH) Q2 revenue rose 16% to $27.2M. IGC Pharma (IGC) expects Phase 2 topline results for IGC-AD1 in Q4 2026.
6 min read
